Our data show that the higher expression of CD68, CD163, and CD206 in BMB samples is a remarkable phenomenon during the transformation of CP to AP and BP in CML patients in contrast to those in control group. The gene discussed is MRC1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.